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Respiratory-distress syndrome (RDS) in the newborn is a major cause of neonatal mortality and morbidity. Although
prematurity is the most-important risk factor for RDS, the syndrome does not develop in many premature infants.
The main cause of RDS is a deficiency of pulmonary surfactant, which consists of phospholipids and specific
proteins. The genes underlying susceptibility to RDS are insufficiently known. The candidate-gene approach was
used to study the association between the surfactant protein A (SP-A) gene locus and RDS in the genetically
homogeneous Finnish population. In the present study, 88 infants with RDS and 88 control infants that were
matched for degree of prematurity, prenatal glucocorticoid therapy, and sex were analyzed for SP-A genotypes. We
show that certain SP-A1 alleles (6A2 and 6A3) and an SP-A1/SP-A2 haplotype (6A2/1A0) were associated with RDS.
The 6A2 allele was overrepresented and the 6A3 allele was underrepresented in infants with RDS. These associations
were particularly strong among small premature infants born at gestational age !32 wk. In infants protected from
RDS (those that had no RDS, despite extreme prematurity and lack of glucocorticoid therapy), compared with
infants that had RDS develop despite having received glucocorticoid therapy, the frequencies of 6A2 (.22 vs. .71),
6A3 (.72 vs. .17), 6A2/1A0 (.17 vs. .68), 6A3/1A1 (.39 vs. .10), and 6A3/1A2 (.28 vs. .06) in the two groups,
respectively, were strikingly different. According to the results of conditional logistic-regression analysis, diseases
associated with premature birth did not explain the association between the odds of a particular homozygous SP-
A1 genotype (6A2/6A2 and 6A3/6A3) and RDS. In the population evaluated in the present study, SP-B intron 4
variant frequencies were low and had no detectable association with RDS. We conclude that the SP-A gene locus
is an important determinant for predisposition to RDS in premature infants.
Introduction
Respiratory-distress syndrome (RDS [MIM 267450]) in
the newborn is the main cause of mortality and mor-
bidity in prematurely born infants. RDS is characterized
by deficient gas exchange that is caused by diffuse ate-
lectasis and high-permeability lung edema and that re-
sults in fibrin-rich alveolar deposits called “hyaline mem-
branes” (hyaline-membrane disease). Deficiency in lung
surfactant is the main cause of RDS (Avery and Mead
1959; for a review, see Merritt et al. 1993). Surfactant
consists of lipids and specific surfactant proteins A–C
(SP-A–SP-C). Its main function is to lower surface ten-
sion at the air-liquid interface of the alveolus, thus pre-
venting diffuse atelectasis (Hawgood and Clements
1990). Lung effluent in RDS is deficient in surfactant
components (Hallman et al. 1991), and the lungs of
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infants that have died of RDS have low levels of sur-
factant proteins (deMello et al. 1989, 1993). Surfactant
components in the amniotic fluid can predict the risk of
RDS (Gluck et al. 1971; Hallman 1992). Moreover, lev-
els of SP-A have been associated with severity of RDS
(Moya et al. 1994).
Although prematurity is the most-important risk fac-
tor for RDS, the syndrome does not develop in many
premature infants. Race, sex, and maternal diseases are
among the risk factors affecting the incidence of RDS
(Farrell and Wood 1976; Richardson and Torday 1994).
Antenatal glucocorticoid therapy (Crowley 1995) and
surfactant supplementation at birth (Merritt et al. 1993)
reduce the incidence of RDS. According to the results
of a twin study, genetic factors contribute to the etiology
of RDS (Myrianthopoulos et al. 1971). Although the
findings of other studies point to hereditary factors hav-
ing a role in RDS as well (Graven and Mesenheimer
1965; Lankenau 1976; Olowe and Akinkugbe 1978;
Hafez et al. 1989), the specific genes underlying sus-
ceptibility to RDS have not been identified. Because
multiple factors can contribute to the pathogenesis of
RDS, the etiology of RDS is thought to be multifactorial
and/or multigenic (Floros and Kala 1998).
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Table 1
Characteristics of the Infants with RDS and the Controls
Characteristic
Infants with RDS
( )n = 88
Controls
( )n = 88
Gestational age (wk)a 31.6 5 2.6 31.7 5 2.6
Birth weight (g)b 1,788 5 646 1784 5 604
Male sex (n) 56 56
Female sex (n) 32 32
Prenatal glucocorticoid (n) 50 50
Premature birth (n):c
Spontaneous vaginal 12 24
PROM 16 22
Twin pregnancy 25 17
Preeclampsia 15 10
Placental ablation 7 2
Other 10 10
Term birth (n)d 3e 3
a Mean 5 SD (23.6–37.4 wk [for infants with RDS] vs. 23.0–37.4
wk [for controls]).
b Mean 5 SD (570–3,280 g [for infants with RDS] vs. 630–3,860
g [for controls]).
c Gestation !37.0 wk.
d Gestation >37.0 wk.
e All three infants recovered from RDS and did not have an SP-B
exon 4 insertion mutation (121ins2).
Deficiency in the synthesis of either phospholipids or
surfactant proteins could be responsible for compro-
mised surface activity. Congenital defects in phospho-
lipid metabolism would be likely to cause multiple dis-
orders. On the other hand, variability in the genes
encoding surfactant proteins could explain some of the
genetic predisposition to RDS. The results of American
population-based studies that include both white and
black subjects and that examine SP-A and SP-B as can-
didate genes (Floros et al. 1995; Kala et al. 1998) show
significant associations between certain subgroups of
RDS and SP-A and/or SP-B alleles.
The human SP-A gene locus, which consists of two
highly homologous functional SP-A genes (SP-A1 and
SP-A2) and a pseudogene, has been assigned to chro-
mosome 10q22-q23 (Bruns et al. 1987; Fisher et al.
1987). Both SP-A genes consist of four coding exons.
Although both gene products may be needed for fully
functional mature human SP-A protein (Voss et al.
1991), individually expressed SP-A genes are also bioac-
tive (Wang et al., in press). SP-A improves both the
surface activity of surfactant and the resistance against
surfactant inhibitors that accumulate in alveolar space
in high-permeability lung edema (Hallman et al. 1991;
Jobe 1994); however, SP-A deficiency does not result in
respiratory failure in mice born at term (Ikegami et al.
1998). As a member of the mammalian C-type lectin
family, SP-A also participates in host defense (for a re-
view, see Crouch 1998). Several alleles that differ by a
single amino acid have been identified for each SP-A
gene (Floros et al. 1996; DiAngelo et al., in press). The
alleles of the SP-A1 gene are denoted as “6An,” and
those of the SP-A2 gene as “1An” (Karinch and Floros
1995; Floros and Hoover 1998). On the basis of its
high-heterozygosity index and polymorphism-informa-
tion-content values, the SP-A locus has the character-
istics of a good genetic marker (Floros et al. 1996).
There is conflicting evidence regarding the role of SP-
A in surfactant function. According to the hypothesis
examined in the present study, deficiency in SP-A con-
tributes to susceptibility to RDS. We have evaluated the
association between the SP-A gene locus and the risk of
RDS in the Finnish population, which is characterized
by homogeneity (de la Chapelle 1993, Peltonen et al.
1995). The data presented here indicate that the human
SP-A locus affects predisposition to RDS.
Subjects and Methods
Protocol and Study Population
The present study was performed at the Children’s
Hospital, Oulu University Central Hospital, Oulu, Fin-
land; the Central Hospital of Southern Ostrobotnia, Sei-
na¨joki, Finland; and the Children’s Hospital, University
Central Hospital, Tampere, Finland. The ethics com-
mittees of these centers approved the study protocol. The
parents of the neonates gave written consent for their
infants’ blood samples to be used in this study. Samples
were collected from infants born in 1996–99.
Clinical data on sex, gestational age, and maternal
and neonatal clinical histories were obtained from the
medical records. The diagnosis of RDS was made on the
basis of the published clinical (grunting, retraction, flar-
ing, need for supplemental O2 for >48 h, or need for
exogenous surfactant therapy), radiographic (diffuse re-
ticulogranular pattern and air bronchograms), and/or
pathologic (diffuse atelectasis and hyaline membranes)
criteria. None of the newborns had been treated with
surfactant prophylactically.
The infants with RDS were matched pairwise to those
without RDS, on the basis of the following criteria: (1)
sex, (2) length of gestation (within one week), and (3)
prenatal glucocorticoid treatment for prevention of
RDS. Twin pairs were not matched with each other. In-
fants were excluded from the study either if intrauterine
blood transfusion was given or if one or both parents
were not of Finnish origin. Altogether, 88 pairs could
be matched. These 176 infants were further studied. Ta-
ble 1 lists the clinical data for the patients. Three infants
with RDS were born at term (i.e., at gestation >37.0
wk). Cord-blood specimens were obtained from all in-
fants born at term during one month ( ) at Oulun = 225
University Central Hospital. These specimens were gen-
otyped. In this general population, none of the infants
had RDS, which is a rare disease in infants born at term.
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DNA Samples
Whole-blood samples (0.5–3 ml) from the umbilical
cord were collected into plastic EDTA tubes and were
stored at 2707C until they were sent to the laboratory
of the Department of Pediatrics, Oulu University Central
Hospital, for genetic analysis. Genomic DNA was iso-
lated from the whole-blood specimens by use of the Pur-
egene DNA Isolation Kit (Gentra Systems). An aliquot
of the DNA solution was diluted to 50 ng/ml, for use in
the PCR amplification. When whole-blood samples were
not available (for 55 subjects), genotypes were deter-
mined by use of a blood spot dried on a filter paper. A
3-mm disk (corresponding to ∼12,000 white blood cells)
was punched from the blood spot on the paper, by use
of a handheld paper punch (Wallac). To decontaminate
the punch between samples, multiple punches were done
on clean filter paper. DNA was bound to the disk, and
cellular contaminants were released by three successive
15-min incubations with 50 ml DNA purification solu-
tion (Gentra Systems), followed by three washes with
100% ethanol. After drying at either 557C or room tem-
perature, the purified paper disk was directly used as a
template for PCR amplification. A blank paper disk
treated in a similar manner was included in each series,
as a control for DNA cross-contamination.
Genotyping of SP-A Genes
Genotyping of both SP-A genes was performed as de-
scribed elsewhere (DiAngelo et al. 1999). In brief, SP-A
genes were amplified with the use of gene-specific prim-
ers, under conditions described elsewhere (Floros et al.
1996). Genomic SP-A1 and SP-A2 clones were used as
controls of gene specificity in each set of PCR reactions.
PCR-cRFLP–based methodology was used to detect sin-
gle-nucleotide polymorphisms at codons 19, 50, 62, 133,
and 219 (for the SP-A1 gene) and at codons 9, 91, 140,
and 223 (for the SP-A2 gene). Codon 85 was analyzed
for both genes, to further ensure the gene specificity of
the PCR amplifications. Various combinations of poly-
morphisms at these sites distinguish different alleles. At
present, 19 alleles have been described for the SP-A1
gene 6An (DiAngelo et al. 1999; R. Ra¨met, R. Haataja,
R. Marttila, A.-M. Ha¨ma¨la¨inen, M. Knip, and M. Hall-
man, unpublished data). For 22 whole-blood specimens,
genotyping was done by use of allele-specific oligonu-
cleotide probes, as described elsewhere (Floros et al.
1996). A total of 100 specimens were analyzed with the
use of both methods. The results were identical in each
case.
Genotyping of the SP-B Intron 4 Length Variation
(SP-B Di4)
Genotyping of SP-B Di4 polymorphism (Floros et al.
1995) was performed with the use of a PCR fragment
amplified with the use of forward primer SPBi4F 5′ CTG-
GTCATCGACTACTTCCA 3′ and reverse primer
SPBi4R 5′ TGAAGGGCACGTAGTTTCCTA 3′. PCR
was conducted in 15 ml reaction mixture containing 50
ng genomic DNA, 0.2 mM each dNTP, 0.6 mM each
primer, 1 # GeneAmp PCR buffer (10 mM Tris-HCl
pH 8.3, 50 mM KCl, 1.5 mM MgCl2, and 0.001% w/
v gelatin), and 0.75 U AmpliTaq Gold DNA polymerase
(PE Biosystems). Samples were initially heated at 947C
for 10 min. Thereafter, they went through 5 cycles at
947C for 2 min, 557C for 30 s, and 727C for 2 min 30
s; then 30 cycles at 947C for 1 min, 557C for 30 s, and
727C for 2 min 30 s; and then a final extension at 727C
for 8 min (Thermal cycler PTC-200; MJ Research). The
resulting 240–590-bp PCR fragments were analyzed in
ethidium bromide–stained LE (BIOzym) or on NuSieve
GTG (FMC BioProducts) agarose gels. The blood sam-
ples on paper were amplified as described above, with
the exception that the reaction volume was 20 ml. The
most-common SP-B Di4 fragment (510 bp) was denoted
as the “invariant allele.” All deletion variants (five dif-
ferent sizes) were pooled together as the deletion alleles.
The most-common deletion variant (366 bp) accounted
for ∼80% of all deletion alleles; others (240, 330, 400,
and 480 bp) were less frequent. In this population sam-
ple, only one insertion-variant allele (590 bp) was de-
tected at a frequency of .013.
Statistical Analysis
Allele-frequency comparisons were performed with
the use of analysis. Allele distributions in infants with2x
RDS and controls were compared with the use of 2 #
tables. Frequencies of individual alleles were comparedk
by use of tables. Fisher’s exact test was used when2 # 2
an expected value was !5. The odds ratios (ORs) and
95% confidence intervals (95% CIs) of RDS were cal-
culated by means of the Woolf (logit) method. The ob-
served genotype frequencies were compared with ex-
pected Hardy-Weinberg distributions, by use of 2x
analysis. Logistic-regression analysis was used to inves-
tigate whether the diseases resulting in premature birth
were associated with the odds of RDS and whether the
association between the SP-A1 allele frequencies and
RDS was independent of diseases causing premature
birth. The ORs of allelic variables and potential con-
founders (spontaneous premature vaginal birth, pre-
mature rupture of fetal membranes [PROM], preeclamp-
sia, and twin pregnancy) for RDS were estimated by use
of conditional regression models. Two sets of indepen-
dent variables were included. Set 1 included four di-
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Figure 1 A, Distribution of SP-A1 alleles. B, Distribution of SP-
A2 alleles. C, Distribution of the major SP-A1/SP-A2 haplotypes. Al-
together, 88 infants with RDS and 88 controls matched for the degree
of prematurity, prenatal glucocorticoid therapy, and sex were analyzed.
Horizontal lines represent allele frequencies of term infants. The P
values, ORs, and 95% CIs, which illustrate the association of indi-
vidual alleles with RDS, are shown below the histograms. An asterisk
(*) above the histogram indicates .P ! .05
chotomous covariates for the etiology of premature
birth, and set 2 included two variables for alleles 6A2
and 6A3 classified into three categories. The software
used for computations included SPSS for Windows (for
basic statistical calculations), Arcus Quickstat (for 2x
analysis and Fisher’s exact test), and Egret for Windows
(for conditional logistic-regression analysis).
Results
Association between SP-A Alleles and RDS
DNA samples from 88 infants with RDS and from
control infants matched for the degree of prematurity,
prenatal glucocorticoid therapy, and sex were ana-
lyzed. There was a significant difference in SP-A1
( )—but not SP-A2 ( )—allele distribu-P = .017 P = .23
tions in infants with RDS, compared with controls.
The SP-A1 allele 6A2 was overrepresented in infants
with RDS, compared with that in controls (frequency
.65 vs. .52, respectively; ). Likewise, the SP-P = .017
A1 allele 6A3 was underrepresented in infants with
RDS, compared with that in controls (frequency .24
vs. .34, respectively; ) (fig. 1A). Infants withP = .034
RDS showed a trend toward overrepresentation of the
SP-A2 allele 1A0 (frequency .63 [in those with RDS]
vs. .54 [in controls]; ), which is in linkage dis-P = .11
equilibrium with 6A2 (Floros et al. 1996, R. Ra¨met,
R. Haataja, R. Marttila, A.-M. Ha¨ma¨la¨inen, M. Knip,
and M. Hallman, unpublished data) (fig. 1B). The fre-
quency of the SP-A1/SP-A2 haplotype 6A2/1A0 was
significantly higher in infants with RDS than in con-
trols (.62 vs. .50, respectively; ) (fig. 1C). InP = .018
term infants ( ), the frequencies of the 6A2, 6A3,n = 225
and 1A0 alleles and of the 6A2/1A0 haplotype were
.60, .26, .59, and .57, respectively.
The frequency of the SP-A1 6A2/6A2 genotype tended
to be different in infants with RDS and controls (.43 vs.
.31, respectively; ), whereas the frequency of theP = .086
heterozygous 6A2/* genotype was similar in the two
groups (.43 vs. .43; ). Similarly, the frequency ofP = 1.0
the 6A3/6A3 genotype differed in infants with RDS and
controls (.034 vs. .15, respectively; , OR .20,P = .009
95% CI .06–.74), whereas the frequency of the hetero-
zygous 6A3/* genotype did not differ in the two groups
(.41 vs. .39, respectively; ). The frequency of theP = .76
homozygous SP-A2 genotype 1A0/1A0 tended to be dif-
ferent in infants with RDS and controls (.40 vs. .28,
respectively; ), whereas the frequency of the het-P = .11
erozygous 1A0/* genotype was similar (.45 vs. .51, re-
spectively; ). The somewhat similar results for theP = .45
SP-A1 allele 6A2 and the SP-A2 allele 1A0 were consistent
with the fact that these two genes are in strong linkage
disequilibrium, which is also evident in this study pop-
ulation. The observed frequency distributions did not
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Figure 2 A, SP-A1 allele distribution in 46 infants with RDS
and 43 controls born at gestation !32 wk. B, SP-A1 allele distribution
in 42 infants with RDS and 45 controls born at gestation >32 wk.
Horizontal lines represent allele frequencies of term infants. The P
values, ORs, and 95% CIs, which illustrate the association of indi-
vidual alleles with RDS, are shown below the histograms. An asterisk
(*) above the histogram indicates .P ! .05
deviate from Hardy-Weinberg equilibrium (data not
shown).
Influence of Risk Factors on Association between RDS
and Either SP-A Alleles or Haplotypes
Prematurity is the most-important risk factor for RDS.
The allele frequencies of both SP-A genes in infants with
RDS and controls were determined separately for infants
born at gestation !32 wk and those born at gestation
132 wk. The median gestational age in the present study
was 32 wk. The association between RDS and the SP-
A gene locus tended to be dependent on the degree of
prematurity (fig. 2A and B). Infants born at gestation
>32.0 wk showed no significant differences in the dis-
tribution of the SP-A1 ( ) or SP-A2 ( ) al-P = .56 P = .53
leles in infants with RDS, compared with controls. In
contrast, among infants born at gestation !32 wk, there
was a difference in SP-A1 ( ) allele distributionP = .036
but no difference in SP-A2 ( ) allele distribution,P = .26
in a comparison of infants with RDS and controls. The
frequency of the SP-A1 allele 6A2 was .66 in infants with
RDS, compared with .49 in controls ( ; fig. 2A).P = .018
Similarly, the frequency of the SP-A1 allele 6A3 was
lower in infants with RDS than it was in controls (.21
vs. .37, respectively; ). In very premature in-P = .015
fants, the frequency of the homozygous SP-A1 genotype
6A2/6A2 tended to differ in infants with RDS, compared
with controls (.48 vs. .30, respectively; ). In con-P = .090
trast, the frequency of the heterozygous 6A2/* genotype
did not differ in the two groups (.37 vs. .37; ).P = .98
The frequency of the homozygous 6A3/6A3 genotype dif-
fered in infants with RDS and controls (.022 vs. .21,
respectively; ), whereas the frequency of the het-P = .006
erozygous 6A3/* genotype did not differ in the two
groups (.37 vs. .30, respectively; ). A similar trendP = .50
was observed for the frequency of the homozygous SP-
A2 genotype 1A0/1A0 (.44 vs. .28 in infants with RDS
and controls, respectively; ) and for the hetero-P = .13
zygous SP-A2 genotype 1A0/* (.43 and .47 in infants
with RDS and controls, respectively; ).P = .77
The incidence of RDS is higher in males than in fe-
males (Farrell and Wood 1976). Taking this into ac-
count, we separately determined, for males (56 pairs)
and females (32 pairs), the differences in the frequencies
of the SP-A alleles in infants with RDS and controls. In
infants with RDS, the frequency distribution of SP-A1
was similar in males and females ( ). In both malesP = .40
and females, the frequency of 6A3 tended to be lower in
infants with RDS, compared with controls, whereas the
frequency of 6A2 tended to be higher in infants with
RDS, compared with controls (data not shown).
Glucocorticoid therapy in threatened premature birth
reduces the risk of RDS. The least-susceptible infants are
those that, despite very premature birth and lack of an-
tenatal corticosteroid therapy, do not have RDS develop.
Among infants born at gestation !32 wk, there was a
striking difference between those that had received ster-
oid therapy and had RDS develop ( ) and thosen = 36
that had not received steroid therapy and did not have
RDS develop ( ; fig. 3A). In the group that did notn = 9
receive steroid therapy and did not have RDS develop,
the frequency of SP-A1 allele 6A2 was .22, compared
with a frequency of .71 in the group that had received
steroid therapy and had RDS develop ( ). Cor-P = .0002
respondingly, the frequency of the SP-A1 allele 6A3 dif-
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Figure 3 A, Distribution of the SP-A1 alleles. B, Distribution of
SP-A2 alleles. C, Distribution of SP-A1/SP-A2 haplotypes in the two
groups of premature infants born at gestation !32 wk. RDS, antenatal
glucocorticoid ( ); no RDS, no glucocorticoid ( ). Horizontaln = 36 n = 9
lines represent allele or haplotype frequencies of term infants. The P
values, ORs, and 95% CIs, which illustrate the association of indi-
vidual alleles with RDS, are shown below the histograms. An asterisk
(*) above the histogram indicates .P ! .05
Figure 4 SP-A1 allele distribution in infants divided into the
following subgroups defined by the length of gestation at birth: !32
wk ( ); 32–36 wk ( ); >37 wk ( ).n = 89 n = 81 n = 231
fered remarkably in these two groups (.72 [in those with
RDS] vs. .17 [in controls]; ). In the controlsP ! .0001
(i.e., those that did not receive steroid therapy and did
not have RDS develop; gestation !32 wk), the 6A2 fre-
quency was lower ( ) and the 6A3 frequency wasP = .016
higher ( ) than the corresponding frequenciesP ! .0001
in infants born at term. Distribution of SP-A2 alleles
was different as well (fig. 3B). In the controls (i.e., those
that did not receive steroid therapy and did not have
RDS develop; gestation !32 wk), the 1A0 frequency was
lower ( ) and the 1A1 ( ) and 1A2 (P = .005 P = .010 P =
) frequencies were higher than the corresponding.048
frequencies in the infants with RDS, and the 1A0 fre-
quency was lower than that in the infants born at term
( ).P = .030
Figure 3C shows the distribution of the haplotypes
between those small premature infants that received ster-
oid therapy and had RDS develop and those that did
not receive prenatal steroid therapy and did not have
RDS develop. Besides 6A2/1A0 ( ), both 6A3/P ! .0001
1A1 ( ) and 6A3/1A2 ( ) had different dis-P = .006 P = .012
tributions in infants with RDS and controls.
SP-A1 Genotypes and Causes of Premature Birth as
Determinants of RDS
SP-A allele distribution was studied in relation to the
length of gestation. None of the SP-A alleles or haplo-
types was associated with the degree of prematurity in
the population evaluated in the present study ( ).n = 401
Figure 4 shows the results for the SP-A1 gene. There
were no detectable differences in the distribution of the
SP-A1 or SP-A2 alleles, among infants born prematurely
as a result of spontaneous vaginal birth ( ; twinn = 36
pregnancies excluded), PROM ( ; twin pregnanciesn = 38
excluded), twin pregnancy ( ), or preeclampsian = 42
( ; twin pregnancies excluded) (data not shown).n = 25
To ascertain the differences in the distribution of SP-
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Table 2
Conditional Logistic-Regression Analysis of the Factors Associated with the Odds of RDS among Premature
Infants: Causes of Premature Birth and SP-A1 Allele 6A2
CAUSE OF PREMATURITY
RESULTS OF CONDITIONAL LOGISTIC-REGRESSION






OR (95% CI) P OR (95% CI) P OR (95% CI) P
Spontaneous vaginal birth .46 (.19–1.07) .070 1.47 (.64–3.41) .37 2.29 (.93–5.66) .071
PROM .53 (.23–1.23) .14 1.82 (.81–4.13) .15 3.01 (1.22–7.44) .017
Twin pregnancy 4.50 (1.17–17.29) .029 1.53 (.66–3.52) .32 2.99 (1.19–7.51) .020
Preeclampsia 1.48 (.61–3.57) .38 1.72 (.76–3.88) .19 2.64 (1.09–6.39) .031
All causes 1.77 (.79–3.97) .16 2.71 (1.12–6.52) .026
NOTE.—In the series of conditional logistic-regression models, individual perinatal disease (yes or no) and/
or 6A2 genotype (no, heterozygote, or homozygote) were the independent variables. The known confounding
variables—length of gestation, fetal sex, and antenatal glucocorticoid treatment—were matched in each stratum.
a X = any allele other than 6A2.
A alleles in infants with RDS compared with paired con-
trols, we used conditional logistic-regression analysis.
We tested the hypothesis of whether an allele of SP-A
influences the odds of RDS, regardless of the etiology of
prematurity. The following conditions that resulted in
premature birth were studied: spontaneous premature
vaginal delivery, PROM, twin pregnancy, and pree-
clampsia. Multiple pregnancy increased the odds of
RDS, whereas spontaneous premature birth tended to
reduce the odds of RDS (tables 2 and 3). Heterozygous
status of 6A2 (table 2) or 6A3 (table 3) did not influence
the odds of RDS. In contrast, the homozygous 6A3 ge-
notype reduced the odds of RDS, regardless of the cause
of premature birth (table 3). With the exception of pre-
maturity associated with spontaneous vaginal delivery,
the homozygous 6A2 genotype increased the odds of
RDS (table 2).
SP-B Di4
It has been suggested elsewhere (Floros et al. 1995)
that there is an association between SP-B Di4 and either
RDS or prematurity. We studied the frequency of Di4
variants in the Finnish population. As shown in table 4,
the frequencies of the deletion and, especially, the in-
sertion variants were low. No detectable differences in
the frequencies of SP-B Di4 alleles were evident in either
a comparison of infants with RDS and controls or a
comparison of premature infants and term infants (data
not shown).
Discussion
RDS is a multifactorial disease that principally affects
infants that are born prematurely. The results of previous
studies have pointed to surfactant proteins A and B hav-
ing a role in the genetic susceptibility to RDS (Floros et
al. 1995; Kala et al. 1998). Taking advantage of the
homogeneity of the Finnish population, we have studied
the associations between SP-A alleles and RDS. In the
present study, we genotyped 88 infants with RDS and
88 control infants that were matched pairwise for length
of gestation, sex, and prenatal glucocorticoid therapy.
We showed that RDS was associated with SP-A1 alleles
( ), with a homozygous SP-A1 genotype (P = .017 P =
), and with an SP-A1/SP-A2 haplotype ( )..009 P = .018
Certain SP-A alleles can be viewed as susceptibility (6A2)
or protective (6A3) factors for RDS. Heterozygous status
of any SP-A allele did not affect the odds of RDS. In
contrast, the homozygous 6A3 genotype significantly de-
creased the odds of RDS, whereas the homozygous 6A2
genotype increased the odds of RDS, even after adjust-
ment for potential confounding variables. The data from
the present study are consistent with previous findings
from a study of white American subjects with RDS (Kala
et al. 1998), in that they underline the role of the SP-A
locus in the susceptibility to RDS in the white popula-
tion. Finally, the present study demonstrates the influ-
ence of steroid treatment and prematurity on the asso-
ciation between SP-A alleles and RDS.
The results of animal studies in which SP-A–deficient
mice were evaluated have raised questions about
whether SP-A proteins have a role in the maintenance
of alveolar stability, which is compromised in RDS. SP-
A–deficient mice born at term do not have respiratory
failure develop (Korfhagen et al. 1996; Ikegami et al.
1998), unlike SP-B–deficient humans or mice (Nogee et
al. 1994; Tokieda et al. 1997; Lin et al. 1998). RDS is
mainly associated with prematurity, however, and, al-
though SP-A may not be essential for the respiratory
function at term, it may be important for alveolar sta-
bility after premature birth. We postulate that SP-A pro-
teins have a role in the pathogenesis of RDS.
The risk of RDS increases as a function of the degree
of prematurity, presumably because of insufficient dif-
ferentiation of the surfactant system (Gluck et al. 1971).
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Table 3
Conditional Logistic-Regression Analysis of the Factors Associated with the Odds of RDS among
Premature Infants: Causes of Premature Birth and SP-A1 Allele 6A3
CAUSE OF PREMATURITY
RESULTS OF CONDITIONAL LOGISTIC-REGRESSION






OR (95% CI) P OR (95% CI) P OR (95% CI) P
Spontaneous vaginal birth .44 (.19–1.02) .056 .86 (.42–1.78) .69 .24 (.06–.89) .033
PROM .47 (.19–1.14) .094 .76 (.36–1.59) .46 .16 (.04–.64) .009
Twin pregnancy 4.03 (1.08–15.04) .038 .79 (.38–1.64) .52 .19 (.05–.74) .016
Preeclampsia 1.82 (.73–4.54) .20 .79 (.38–1.62) .52 .19 (.05–.72) .015
All causes .82 (.40–1.68) .59 .21 (.06–.77) .019
NOTE.—In the series of conditional logistic-regression models, individual perinatal disease (yes or no)
and 6A3 genotype (no, heterozygote, or homozygote) were the independent variables. The known con-
founding variables—length of gestation, fetal sex, and antenatal glucocorticoid treatment—were matched
in each stratum.
a X = any allele other than 6A3.
Table 4
SP-B Di4 Polymorphism: Di4 Allele Distribution in Infants with RDS and Controls
GROUP AND SP-B Di4
POLYMORPHISM
NO. (%) of Di4 ALLELES IN
P OR (95% CI)Infants with RDSa Controlsb
n = 88 n = 88
All pairs:
Invariant 155 (88.1) 157 (89.2) .74 .89 (.46–1.73)
Deletion 18 (10.2) 15 (8.5) .58 1.22 (.60–2.51)
Insertion 3 (1.7) 4 (2.3) 1.0 .75 (.16–3.38)
n = 46 n = 43
Gestation !32 wk:
Invariant 80 (87.0) 78 (90.7) .43 .68 (.27–1.76)
Deletion 9 (9.8) 7 (8.1) .70 1.22 (.44–3.44)
Insertion 3 (3.3) 1 (1.2) .62 2.87 (.29–28.1)
n = 42 n = 45
Gestation >32 wk:
Invariant 75 (89.3) 79 (87.8) .76 1.16 (.46–2.96)
Deletion 9 (10.7) 8 (8.9) .69 1.23 (.45–3.35)
Insertion 0 3 (3.3) 1.2 0.15 (.01–2.51)
n = 36 n = 9
Gestation !32 wk subgroups:
Invariant 61 (84.7) 15 (83.3) 1.0 1.11 (.27–4.48)
Deletion 8 (11.1) 3 (16.7) .69 .63 (.15–2.64)
Insertion 3 (8.3) 0 .58 1.86 (.09–37.7)
a In the subgroups of infants born at gestation !32-wk, the infants with RDS ( ) hadn = 36
received steroid therapy.
b In the subgroups of infants born at gestation !32-wk, the controls ( ) had no RDS andn = 9
had not received steroid therapy.
Low SP-A protein level in lung effluent before (Hallman
et al. 1988) and shortly after birth (Moya et al. 1994)
is closely associated with RDS. Similarly, low levels of
SP-A are found in the lungs of infants that have died
of RDS (deMello et al. 1989) or that have had chronic
lung disease develop (Hallman et al. 1991). It is inter-
esting that the SP-A mRNA levels are shown to differ
among adult humans (Floros et al. 1991; Karinch et al.
1997). The 6A26A2/1A01A0 genotype, which was as-
sociated with RDS in the present study, correlated with
low mRNA levels (Karinch et al. 1997). One may pro-
pose that an infant with this genotype has an insufficient
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amount of SP-A at a critical stage of development, com-
pared with those infants with other genotypes. Accord-
ing to the findings of the present study, the critical stage
in development occurs considerably before term. The
importance of the SP-A genotype, in relation to indi-
vidual predisposition to RDS, was supported by the
results of a comparison of premature infants that, de-
spite having received steroid therapy, had RDS develop
and controls that had not received steroid therapy be-
fore premature birth. In infants without RDS, the fre-
quencies of alleles 6A2 and 6A3 were remarkably low
(22.2%) and high (72.2%), respectively. The opposite
was true in the group of infants that, despite having
received glucocorticoid therapy, had RDS develop (fre-
quency 70.8% [for those with 6A2] and 16.7% [for
those with 6A3]). SP-A2 alleles and SP-A haplotypes
were also strikingly associated with RDS (fig. 3). Similar
to the findings of the present study, the SP-A2 allele 1A0
tended to be increased in the white population with
RDS, as shown by Kala et al. (1998). The SP-A1 and
SP-A2 genetic loci are linked, and 6A2/1A0 is the major
haplotype (Floros et al. 1996; the present study).
Infants who did not have RDS develop, despite pre-
maturity and lack of steroid therapy, had a low fre-
quency of the 6A2 allele and a high frequency of the
6A3 allele. Of relevance is the finding, from in vitro
studies, that the responses of the 6A2 and 6A3 alleles to
glucocorticoid treatment were different (Hoover and
Floros 1999). Although neither the mechanisms in-
volved nor how these observations reflect the in vivo
situation are presently understood, these observations
support the notion that the genotype of the individual
plays a role in the pathogenesis of RDS and/or in the
response to glucocorticoid therapy. Moreover, the ob-
servation that the 6A26A2/1A01A0 genotype correlates
with low levels of SP-A mRNA (Karinch et al. 1997)
supports data from the present study. Inactivation of
surfactant by plasma proteins is an attractive patho-
physiologic mechanism. The high-permeability lung
edema caused by increased alveolar and capillary per-
meability, which is significantly associated with the de-
gree of prematurity, is a characteristic feature in cases
of RDS (Jobe 1994). Many plasma components inac-
tivate the surface tension–lowering property of lung sur-
factant. The surfactant concentration and the quality of
surfactant significantly influence the inactivation. SP-A
improves the resistance of surfactant against surfactant
inhibitors in vitro (Cockshutt et al. 1990; Venkitaraman
et al. 1990; Hallman et al. 1991). Furthermore, ac-
cording to the findings from an experimental study in
premature rabbits (Yukitake et al. 1994), the addition
of SP-A to the lipid extract of exogenous surfactant
protected the surfactant against the inhibitory effects of
plasma.
The surface tension–promoting effect of SP-A de-
pends on the presence of SP-B, a hydrophobic surfactant
protein that is essential for alveolar stability (Hawgood
and Clements 1990; Nogee 1994). SP-B Di4 has an as-
sociation with RDS or prematurity in the American pop-
ulation (Floros et al. 1995). In the Finnish population,
the frequencies of the deletion and insertion variants
were low compared with those in the American popu-
lation, and no associations with RDS or prematurity
were detectable (table 4). This does not rule out the
possibility that SP-B gene variability affects the inci-
dence or severity of RDS. Similar to the results of a
previous study demonstrating racial differences in the
allelic distribution at the SP-B gene locus (Veletza et al.
1996), the results of the present study underline the
importance of population homogeneity in studies as-
sociating gene variation with a disease.
The allele 6A2, for which there was an association
with increased odds of RDS, is the most-common SP-
A1 allele. Although the 6A2 allele may associate with
lack of surface activity in premature infants that were
previously destined to die, it can be advantageous in
some other respects. For example, 6A2 may be beneficial
in host defense or inflammatory lung disease (reviewed
by Eggleton and Reid 1999).
In summary, we have shown here that the SP-A gene
locus plays a role in the genetic predisposition to RDS.
This is evident among premature infants born at ges-
tation !32 wk. The mechanisms by which either the 6A2
allele contributes to or the 6A3 allele protects infants
from RDS remain to be clarified.
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